Sally Langa has been appointed vice president, business development, for Catalent’s development and analytical services offerings. Ms. Langa will be responsible for growing the company's early phase development business for small molecule compounds, including analytical services, formulation development and micronization.

Ms. Langa's career within the pharmaceutical services industry spans almost thirty years. She joins Catalent from Halo Pharma, where she served as vice president, sales and marketing. She also held a number of senior positions at Patheon.

“Sally brings a huge amount of experience to Catalent and will be a pivotal part of the team charged with meeting the company’s ambitious growth targets,” said Jonathan Arnold, vice president and general manager of advanced delivery technologies, Catalent. “Catalent sees great growth potential in its early stage development activities, as well as continued opportunity to integrate these services further into the clinical and commercial phases of development.”

Ms. Langa is an active member of the Drug, Chemical and Associated Technologies (DCAT) Association, and is currently on the technology committee. She is also a trustee on the board of the Pharma & Biopharma Outsourcing Association (PBOA).